RCT on the Treatment of Menopausal Syndrome With Chinese Medicine

Menopause Clinical Trial

Official title:

Clinical Trial on the Treatment of Menopausal Syndrome With Chinese Medicine Gui-zhi-fu-ling-wan With Variation and the Mechanism of Anti-inflammation and Body Surface Temperature Distribution

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06074809
• Other study ID #: Menopause study
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: November 1, 2023
• Est. completion date: January 31, 2026

Study information

• Verified date: October 2023
• Source: Chinese University of Hong Kong
• Contact: Hongwei Zhang, PhD
• Phone: 39439845
• Email: zhanghw[@]cuhk.edu.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blinded, randomized, placebo-controlled clinical trial. Subjects will be randomly assigned to the treatment group (Modified Guizhi Fuling granules) or placebo group (Placebo granules) for 8 weeks. Outcomes will be measured at week 8 and week 12.

Description:

Menopausal syndrome is a series of symptoms caused by ovarian follicles degeneration that occurs before or after menopause. These symptoms include central nervous system-related disorders (such as hot flashes, insomnia, depression, anxiety, etc.); metabolic, weight, cardiovascular and musculoskeletal changes; urogenital and skin atrophy; and sexual dysfunction.

Some previous studies have investigated the possibilities of using traditional Chinese medicine (TCM) for the treatment of menopausal syndrome. However, due to the limitations of previous clinical research, more evidence is required to support the efficacy of TCM treatment. Therefore, we propose to conduct a randomized, double-blinded, placebo-controlled clinical trial here, with the hope of objectively assessing the efficacy and safety of using TCM to treat menopausal syndrome.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 78
• Est. completion date: January 31, 2026
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 60 Years

Eligibility

Inclusion Criteria:

• Female subjects with age between 40 and 60 years old;

• For those who have symptoms of primary menopause (irregular menstruation lasting for more than 6 months, or absence of menstrual periods for more than 3 months)

• The score of the physical symptoms in Greene Climacteric Symptom Score (GCS) is 6 or above (average level);

• Have moderate level (affecting certain level of daily activity) or severe (cannot carry out daily activity) hot flashes, defined as transient sensations of heat, sweating, flushing, anxiety and chills lasting for 1-5 minutes;

• Diagnosed Deficiency of Kidney essence and static blood in Lower Jiao by Chinese medicine practitioner

• Agreed to receive Chinese medication or placebo for 2 months upon randomization.

Exclusion Criteria:

• The menopausal syndrome caused by surgical operations or medications (such as chemotherapy, gonadotropin-releasing hormone agonists, etc.).

• Have received estrogen treatment in the past 2 months;

• Have received any medication for treating menopause in the past month, including herbs, non-prescribed drugs, supplements, or change of diet to consume more legumes;

• Known serious emotional, mental or psychological disorders that may affect the study;

• During pregnancy, pre-pregnancy period, or lactation period;

• Known history of allergy to any traditional Chinese medicine;

• Have received anticoagulant or antiplatelet drugs in the past month;

• Known history of some certain serious medical disease, such as cardiovascular disease, liver or renal dysfunction, diabetes, cerebrovascular disease, blood disorders, with unstable conditions;

• Chinese medicine pattern combined with damp phlegm or damp heat, or only deficiency of Yin blood or absence of static blood pattern.

Related Conditions & MeSH terms

• Menopause

Intervention

Drug:
• Modified Guizhi Fuling granules
Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.

Other:
• Placebo
Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.

Locations

Country	Name	City	State
Hong Kong	School of Chinese Medicine	Shatin

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Greene Climacteric Scale (Chinese version)	Greene Climacteric Scale (GCS) is one of the most common scales used to assess menopause. It includes four aspects of symptoms: vasomotor, somatic, psychological, and sexual response. This scale consists of 21 symptoms that can be assessed by patients themselves. The scoring from 0 to 3 in each item, indicates 'Not at all', 'A little bit', 'Much', and 'Very much' respectively.	Week 8
Secondary	Short-Form Health Survey, SF-12v2 (Chinese version)	The SF-12v2 is the brief version of SF-36, consisting of 12 questions related to our physical, mental health and functionality. It is used as a supportive tool to comprehensively assess the health status of the patient. Scores range from 0 to 100, with higher scores representing better self-reported health.	Week 8
Secondary	Short-Form Health Survey, SF-12v2 (Chinese version)	The SF-12v2 is the brief version of SF-36, consisting of 12 questions related to our physical, mental health and functionality. It is used as a supportive tool to comprehensively assess the health status of the patient. Scores range from 0 to 100, with higher scores representing better self-reported health.	Week 12
Secondary	Temperature change of face, limbs and abdomen	The peripheral temperature of the face, limbs and abdomen of the patients will be measured by a thermographic camera.	Week 8
Secondary	Temperature change of face, limbs and abdomen	The peripheral temperature of the face, limbs and abdomen of the patients will be measured by a thermographic camera.	Week 12
Secondary	Level change of sex hormones	Level change of Estradiol (E2) and Follicle-stimulating hormone (FSH) will be measured between baseline and week 8.	Week 8
Secondary	Level change of sex hormones	Level change of Estradiol (E2) and Follicle-stimulating hormone (FSH) will be measured between baseline and week 12.	Week 12
Secondary	Level change of inflammatory markers	Level change of the serum inflammatory factors: high-sensitivity C-reactive protein (hsCRP), Interleukin 6 (IL-6) , Interleukin 8 (IL-8) and Tumor necrosis factor-a (TNF-a) will be measured from baseline to week 8.	Week 8
Secondary	Level change of inflammatory markers	Level change of the serum inflammatory factors: high-sensitivity C-reactive protein (hsCRP), Interleukin 6 (IL-6) , Interleukin 8 (IL-8) and Tumor necrosis factor-a (TNF-a) will be measured from baseline to week 12.	Week 12
Secondary	Greene Climacteric Scale (Chinese version)	Greene Climacteric Scale (GCS) is one of the most common scales used to assess menopause. It includes four aspects of symptoms: vasomotor, somatic, psychological, and sexual response. This scale consists of 21 symptoms that can be assessed by patients themselves. The scoring from 0 to 3 in each item, indicates 'Not at all', 'A little bit', 'Much', and 'Very much' respectively.	Week 12